The study evaluated the safety, tolerability, and immunogenicity of the vaccine candidate. It showed that the vaccine was generally well-tolerated and elicited robust antibody responses compared to those observed in human convalescent serum. The vaccine causes very few adverse events. All subjects in the study developed neutralizing antibodies after two doses of the vaccine. At the 100-µg level, the anti-S1-receptor-binding domain and viral neutralizing antibody levels were comparable to those found in hospitalized patients who had recovered from COVID-19.

UB-612 is stable at normal refrigerator temperatures, allowing for cold chain management within existing infrastructures. The vaccine candidate is designed to mimic natural infection to activate both antibody and T-cell immune systems to generate both protective neutralizing antibodies and cytotoxic T cells against SARS-CoV-2.

Covaxx is currently conducting phase II clinical trials in Taiwan with a grant from Taiwan's Ministry of Health and Welfare. It will also soon start phase II/III trials in India, in partnership with Aurobindo. The company also plans on conducting clinical trials in Brazil. Covaxx has established a logistics partnership with Maersk that will allow it to deliver UB-612 around the world.